Exacerbations in COPD: A burden to curtail;Les exacerbations dans la BPCO: Un fardeau à réduire

Revue Medicale de Liege

Volumn 61, Issue 10, 2006, Pages 691-696

  Corhay, J L ^a   Nguyen Dang, D ^a   Louis, R ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

Chronic obstructive pulmonary disease; Exacerbation; Prevention

Indexed keywords

ACETYLCYSTEINE; CORTICOSTEROID; FLUTICASONE; IPRATROPIUM BROMIDE; PLACEBO; SALMETEROL; TIOTROPIUM BROMIDE;

CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; DISEASE COURSE; DISEASE EXACERBATION; DRUG ACTIVITY; HUMAN; LUNG FUNCTION; META ANALYSIS; MORBIDITY; MORTALITY; QUALITY OF LIFE; REVIEW; SYSTEMATIC REVIEW;

HUMANS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 33847710354     PISSN: 00353663     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (34)

1. Pauwels RA, Buist AS, Calverley PMA, et al. - Global strategy for the diagnosis, management, and prevention of chronic obstructive disease : NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop report. Am J Respir Crit Care Med 2001, 163, 1256-1276 (updated 2003; available at www.goldcopd.com. Accessed December 19, 2003).
2. Donaldson GC, Seemungal TAR, Bhowmik A, Wedzicha JA. - Relationship between exacerbation frequency and lung function decline in chronic obstructive disease. Thorax, 2002, 57, 847-852.
3. Kanner RE, Antonisen NR, Connett JE. - Lower respiratory illness promote FEV1 decline in current smokers but not ex-smokers with mild chronic obstructive pulmonary disease : results from the lung health study. Am J Respir Crit Care Med, 2001, 164, 358-364.
4. Inhaled Steroids in Obstructive Lung Disease in Europe Study Investigators Jones PW, Willits LR, Burge PS, Calverley PM. Disease severity and the effect of fluticasone propionate on chronic obstructive pulmonary disease excacerbations. Eur Respir J, 2003, 21, 68-73.
5. Seemungal TAR, Donaldson GC, Paul EA, et al. - Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med, 1998, 157, 1418-1422.
6. Groenewegen KH, Schols AMVJ, Wouters EFM. - Mortality and mortality-related factors after hospitalization for acute exacerbation of COPD. Chest, 2003, 124, 459-467.
7. Gunen H, Hacievlieyagil SS, Kosar F, et al. - Factors affecting survival of hospitalised patients with COPD. Eur Respir J, 2005, 26, 234-241.
8. Soler-Cataluna JJ, Martinez-Garcia MA, Roman Sanchez P, et al. - Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax, 2005, 60, 925-931.
9. Wouters EF. - Economic analysis of the confronting COPD survey : an overvieuw of results. Respir Med, 2003, 97, S3-S14.
10. Anthonisen NR, Manfreda J, Warren CP, et al. - Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med, 1987, 106, 196-204.
11. Rodrigez-Roisin R. - Toward a consensus definition for COPD exacerbations. Chest, 2000, 117, 398s-401s.
12. Celli BR, MacNee W, and committee members. - Standards for the diagnosis and treatment of patients with COPD : a summary of the ATS/ERS position paper. Eur Respir J, 2004, 23, 932-946.
13. Griffiths TL, Burr ML, Campbell IA, et al. - An outpatient multidisciplinary pulmonary rehabilitation programme was effective in disabling chronic lung disease. Lancet, 2000, 355, 362-368.
14. Burge PS, Calverley PMA, Jones PW, et al. - Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease : the ISOLDE trial. BMJ, 2000, 320, 1297-1303.
15. National Institute for clinical excellence (NICE). Chronic obstructive pulmonary disease: national clinical guideline on management of chronic obstructive pulmonary disease in adults in primary and secondary care. Thorax, 2004, 59, 1-232.
16. van der Valk PD, Monninkhof E, Van der Palen J, et al. - Effect of discontinuation of inhaled corticosteroids in patients with chronic obstructive pulmonary disease: the COPE study. Am J Respir Crit Care Med, 2002, 166, 1358-1363.
17. Jarad NA, Wedzicha JA, Burge PS, Calverley PM. - An observational study of inhaled corticosteroid withdrawal in stable chronic obstructive pulmonary disease. ISOLDE Study Group. Respir Med, 1999, 93, 161-166.
18. Wouters EFM, Postma DS, Fokkens B, et al. and for the COSMIC Study Group. - Withdrawal of fluticasone propionate from combined salmeterol/fluticasone treatment in patients with COPD causes immediate and sustained disease deterioration : a randomised controlled trial. Thorax, 2005, 60, 480-487.
19. Boyd G, Morice AH, Pounsford JC, et al - An evaluation of salmeterol in the treatment of chronic obstructive pulmonary disease (COPD). Eur Respir J, 1997, 10, 815-821.
20. Mahler DA, Wire P, Horstman D, et al. - Effectiveness of fluticasone propionate and salmeterol combination delivered via the discus device in the treatment of chronic obstructive pulmonary disease. Am J Respir crit Care Med, 2002, 166, 1084-1091.
21. Calverley P, Pauwels R, Vestbo J, et al. - Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease : a randomised controlled trial. Lancet, 2003, 361, 449-456
22. Rossi A, Kristufek P, Levine BE, et al. - Comparison of the efficacy, tolerability, and safety of formoterol dry powder and oral, slow-release theophylline in the treatment of COPD. Chest, 2002, 121, 1058-1069.
23. Szafranski W, Cukier A, Ramirez A, et al. - Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur Respir J, 2003, 21, 74-81.
24. Dahl R, Greefhorst LA, Nowak D, et al. - Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease. Am J Respir Crit Care Med, 2001, 164, 778-784.
25. Calverley PM, Boonsawat W, Cseke Z, et al. - Maintenance therapy with budesonide and formoterol in chronicobstructive pulmonary disease. Eur Respir J, 2003, 22, 912-919.
26. Pauwels R, Caverley PMA, Vestbo J, et al. - Reduction of exacerbations with salmeterol/futicasone combination 50/500 meg bd in the treatment of COPD. Eur Respir J, 2002, 20, 241s.
27. Corhay J-L, Louis R. - Le médicament du mois : le tiotropium (Spiriva®). Rev Med Liège, 2004, 59, 530-533.
28. Casaburi R, Mahler DA, Jones PW, et al. - A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J, 2002, 19, 217-224.
29. Vincken W, van Noord JA, Greefhorst APM et al. - Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium. Eur Respir J, 2002, 19, 209-216.
30. Brusasco V, Hodder R, Miravitlles M, et al. - Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. Thorax, 2003, 58, 399-404.
31. Niewoehner DE, Rice K, Cote C, et al. - Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilatator. Ann intern med, 2005, 143, 317-326.
32. Stey C, Steurer J, Bachmann S, et al. - The effect of oral N-acetylcysteine in chronic bronchitis : a quantitative systematic review. Eur respir J, 2000, 16, 253-262.
33. Grandjean EM, Berthet P, Ruffmann R, Leuenberger P. - Efficacy of oral long-term N-acetylcysteine in chronic bronchopulmonary disease : a meta-analysis of published double-blind,placebo-controlled clinical trials. Clin Ther, 2000, 22, 209-221.
34. Decramer M, Rutten-van Molken M, Dekhuijzen PNR, et al. - Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study BRONCUS) : a randomised placebo-controlled trial. Lancet, 2005, 365, 1552-1560.